Filament Health Corp. announced Health Canada approval for a phase 2 clinical trial at the University of British Columbia (UBC). The trial will study the effects of PEX010, Filament's botanical psilocybin drug candidate, for the treatment of opioid use disorder (OUD).

Standard treatment for OUD is opioid agonist therapy (OAT). But less than half of those who start OAT remain for 6 months, and approximately 1 in 10 patients receiving professional help due to an overdose were receiving OAT. There is a critical need for research into new interventions to support those with OUD, and research indicates that psychedelicassisted therapy may be a promising approach.